A Novel Acquired T(2;4)(q36.1;q24) with a Concurrent Submicroscopic Del(4)(q23q24) in An Adult with Polycythemia Vera

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Jun 27

PMID 29941837

Authors

Eigil Kjeldsen

Affiliations

Soon will be listed here.

Abstract

: Polycythemia vera (PV) is a clonal myeloid stem cell disease characterized by a growth-factor independent erythroid proliferation with an inherent tendency to transform into overt acute myeloid malignancy. Approximately 95% of the PV patients harbor the V617F mutation while less than 35% of the patients harbor cytogenetic abnormalities at the time of diagnosis. Here we present a V617F positive PV patient where G-banding revealed an apparently balanced t(2;4)(q35;q21), which was confirmed by 24-color karyotyping. Oligonucleotide array-based Comparative Genomic Hybridization (aCGH) analysis revealed an interstitial 5.4 Mb large deletion at 4q23q24. Locus-specific fluorescent in situ hybridization (FISH) analyses confirmed the mono-allelic 4q deletion and that it was located on der(4)t(2;4). Additional locus-specific bacterial artificial chromosome (BAC) probes and mBanding refined the breakpoint on chromosome 2. With these methods the karyotype was revised to 46,XX,t(2;4)(q36.1;q24)[18]/46,XX[7]. : This is the first report on a PV patient associated with an acquired novel t(2;4)(q36.1;q24) and a concurrent submicroscopic deletion del(4)(q23q24). The study also underscores the benefit of combined usage of FISH and oligo-based aCGH analysis in characterizing chromosomal abnormalities. The present findings provide additional clues to unravel important molecular pathways in PV to obtain the full spectrum of acquired chromosomal and genomic aberrations, which eventually may improve treatment options.

References

Nguyen A, Albers C, Holcombe R . Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. Int J Mol Med. 2010; 26(1):121-5. DOI: 10.3892/ijmm_00000443. View

Fenaux P, Lai J, Quiquandon I, Preudhomme C, Dupriez B, Facon T . Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. Leuk Lymphoma. 2011; 5(2-3):117-25. DOI: 10.3109/10428199109068114. View

Testa J, Kanofsky J, Rowley J, Baron J, Vardiman J . Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol. 1981; 11(1):29-45. DOI: 10.1002/ajh.2830110105. View

Kiladjian J, Gardin C, Renoux M, Bruno F, Bernard J . Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J. 2003; 4(3):198-207. DOI: 10.1038/sj.thj.6200250. View

Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N . Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800. DOI: 10.1111/j.1365-2141.2009.07697.x. View

Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

de Oliveira F, Miguel C, Lucena-Araujo A, de Lima A, Falcao R, Rego E . FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities. Med Oncol. 2013; 30(1):483. DOI: 10.1007/s12032-013-0483-1. View

Andrieux J, Demory J . Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep. 2005; 4(3):224-9. View

10.

He Y, Li B, Li Z, Liu P, Wang Y, Tang Q . Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011; 333(6047):1303-7. PMC: 3462231. DOI: 10.1126/science.1210944. View

11.

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

12.

Babicka L, Ransdorfova S, Brezinova J, Zemanova Z, Sindelarova L, Siskova M . Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. Leuk Res. 2006; 31(1):39-47. DOI: 10.1016/j.leukres.2006.03.010. View

13.

Rege-Cambrin G, Mecucci C, Tricot G, Michaux J, Louwagie A, VAN HOVE W . A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet. 1987; 25(2):233-45. DOI: 10.1016/0165-4608(87)90183-x. View

14.

Tefferi A, Pardanani A, Lim K, Abdel-Wahab O, Lasho T, Patel J . TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009; 23(5):905-11. PMC: 4654629. DOI: 10.1038/leu.2009.47. View

15.

Acar K, Sucak G, Yagci M, Tunca Y, Haznedar R . Translocation (2;11)(p21;q23) in a patient with polycythemia vera: a novel clonal chromosome abnormality. Am J Hematol. 2006; 81(11):891. DOI: 10.1002/ajh.20611. View

16.

Kralovics R, Teo S, Buser A, Brutsche M, Tiedt R, Tichelli A . Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005; 106(10):3374-6. DOI: 10.1182/blood-2005-05-1889. View

17.

Chen E, Schneider R, Breyfogle L, Rosen E, Poveromo L, Elf S . Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2014; 125(2):327-35. PMC: 4287639. DOI: 10.1182/blood-2014-04-567024. View

18.

Moon R, Bowerman B, Boutros M, Perrimon N . The promise and perils of Wnt signaling through beta-catenin. Science. 2002; 296(5573):1644-6. DOI: 10.1126/science.1071549. View

19.

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M . Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004; 117(10):755-61. DOI: 10.1016/j.amjmed.2004.06.032. View

20.

Cerquozzi S, Tefferi A . Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5:e366. PMC: 4670948. DOI: 10.1038/bcj.2015.95. View